New combo targets tough esophageal cancer in 33-patient trial
Disease control
Not yet recruiting
This study tests a combination of two drugs (SHR-1701 and irinotecan liposome) in 33 people with esophageal squamous cell carcinoma who have already received immunotherapy. The goal is to see if the combination can shrink tumors or control the disease. Participants must have meas…
Phase: PHASE2 • Sponsor: Zhigang Li • Aim: Disease control
Last updated May 01, 2026 15:58 UTC